Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in OncologyMargaret von Mehren, Jillian L. Scavone, R. Lor Randall et al.|Journal of the National Comprehensive Cancer Network|2018Cited by 733
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J. Sullivan, Bob T. Li, Manish R. Patel et al.|Cancer Discovery|2017Cited by 418
BRAF Inhibition in <i>BRAF</i> <sup>V600</sup> -Mutant Gliomas: Results From the VE-BASKET StudyThomas Kaley, David M. Hyman, Mehdi Touat et al.|Journal of Clinical Oncology|2018Cited by 330